Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway

Li,Dongfan; Li,Peng; Guo,Zhengtuan; Wang,Huaijie; Pan,Weikang

doi:10.3892/ijmm.2017.2863

Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway

Authors:
- Dongfan Li
- Peng Li
- Zhengtuan Guo
- Huaijie Wang
- Weikang Pan
View Affiliations

Affiliations: Department of Respiratory Medicine, The Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Pediatric Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: January 20, 2017 https://doi.org/10.3892/ijmm.2017.2863
Pages: 757-763

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Approximately 10% of infantile hemangiomas (IHs) are the most common vascular tumors affecting children and are characterized by rapid growth, and can have destructive, disfiguring and even life-threatening consequences. Currently, propranolol is considered to be a safe and effective treatment option for problematic proliferating IHs. Recent studies have also revealed that microRNAs (miRNAs or miRs) play important roles in the regulation of angiogenesis. In this study, XPTS‑1 cells were used as a hemangioma-derived endothelial cell line constructed in our laboratory. Through a series of experiments, we discovered that miR‑382 is a novel miRNA associated with IHs, which was overexpressed in XPTS‑1 cells and was conversely downregulated by treatment with propranolol. In addition, we found that miR‑382 contributes to the progression of IHs. Our results revealed that propranolol inhibited XPTS‑1 cell migration and proliferation, and promoted apoptosis, and these effects were reversed by the restoration of miR‑382 expression by transfection of the cells with an miR‑382 overexpression vector. Further experiments revealed that the above-mentioned effects were associated with the phosphatase and tensin homolog (PTEN)-mediated AKT/mammalian target of rapamycin (mTOR) signaling pathway. The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR‑382. On the whole, our study identified that the downregulation of miR‑382 by propranolol inhibits the progression of IHs via the PTEN-mediated AKT/mTOR pathway.

View Figures

View References

1	Ji Y, Chen S, Li K, Li L, Xu C and Xiang B: Signaling pathways in the development of infantile hemangioma. J Hematol Oncol. 7:132014. View Article : Google Scholar : PubMed/NCBI
2	Yilmaz L, Dangoisse C and Semaille P: Infantile hemangioma and propranolol: a therapeutic 'revolution'. Literature review. Rev Med Brux. 3:4479–4484. 2012.
3	Mulliken JB, Fishman SJ and Burrows PE: Vascular anomalies. Curr Probl Surg. 37:517–584. 2000. View Article : Google Scholar : PubMed/NCBI
4	Drolet BA, Esterly NB and Frieden IJ: Hemangiomas in children. N Engl J Med. 341:173–181. 1999. View Article : Google Scholar : PubMed/NCBI
5	Margileth AM and Museles M: Cutaneous hemangiomas in children. Diagnosis and conservative management. JAMA. 194:523–526. 1965. View Article : Google Scholar : PubMed/NCBI
6	Ji Y, Chen S, Xu C, Li L and Xiang B: The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 172:24–32. 2015. View Article : Google Scholar
7	England RW, Hardy KL, Kitajewski AM, Wong A, Kitajewski JK, Shawber CJ and Wu JK: Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells. Ann Plast Surg. 73(Suppl 1): S119–S124. 2014. View Article : Google Scholar : PubMed/NCBI
8	Laranjo S, Costa G, Paramés F, Freitas I, Martins JD, Trigo C and Pinto FF: The role of propranolol in the treatment of infantile hemangioma. Rev Port Cardiol. 33:289–295. 2014.PubMed/NCBI
9	Hou Y, Sun Y, Shan H, Li X, Zhang M, Zhou X, Xing S, Sun H, Chu W, Qiao G and Lu Y: β-adrenoceptor regulates miRNA expression in rat heart. Med Sci Monit. 18:BR309–BR314. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Møller S, et al: The rectal cancer microRNAome - microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
11	Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer. 50:196–206. 2011. View Article : Google Scholar : PubMed/NCBI
12	Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B, Xu C, Zhang B, Zhang F, Dong D, et al: MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res. 84:434–441. 2009. View Article : Google Scholar : PubMed/NCBI
13	Li P, Xiao XE, Xu Q and Guo ZT: Establishment of human infancy hemangioma-derived endothelial cell line XPTS-1 and animal model of human infancy hemangioma. Zhonghua Kou Qiang Yi Xue Za Zhi. 46:129–133. 2011.In Chinese. PubMed/NCBI
14	Han L, Liang XH, Chen LX, Bao SM and Yan ZQ: SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration. Int J Clin Exp Pathol. 6:2357–2365. 2013.PubMed/NCBI
15	Seok JK, Lee SH, Kim MJ and Lee YM: MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Res. 42:8062–8072. 2014. View Article : Google Scholar : PubMed/NCBI
16	Snaddon J, Parkinson EK, Craft JA, Bartholomew C and Fulton R: Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus. Br J Cancer. 84:1630–1634. 2001. View Article : Google Scholar : PubMed/NCBI
17	Blanco-Aparicio C, Renner O, Leal JF and Carnero A: PTEN, more than the AKT pathway. Carcinogenesis. 28:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI
18	Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Newell B, et al: Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 118:882–887. 2006. View Article : Google Scholar : PubMed/NCBI
19	Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB and Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med. 358:2649–2651. 2008. View Article : Google Scholar : PubMed/NCBI
20	Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L, et al: Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 131:128–140. 2013. View Article : Google Scholar :
21	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar
22	Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI
23	Abdin AA, Soliman NA and Saied EM: Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice. Pharmacol Rep. 66:1114–1121. 2014. View Article : Google Scholar : PubMed/NCBI
24	Miquel J, Bruneau B and Dupuy A: Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol. J Am Acad Dermatol. 70:e83–e84. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yamamoto Y, Kounami S, Okuhira H, Nakamura Y and Furukawa F: Successful treatment of tufted angioma with propranolol. J Dermatol. 41:1120–1122. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lamming DW, Ye L, Sabatini DM and Baur JA: Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 123:980–989. 2013. View Article : Google Scholar : PubMed/NCBI
27	Benjamin D, Colombi M, Moroni C and Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
28	Slomovitz BM and Coleman RL: The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI